Management Team

Management Team

President and Chief Executive Officer
Rahul Singhvi, Sc.D., M.B.A.

Senior Vice President, Commercial Operations
Raymond J. Hage, Jr., M.B.A.

Senior Vice President of International and Government Alliances
John J. Trizzino, B.S., M.B.A.

Vice President, Vaccine Development
Gale Smith, Ph.D.

Vice President, Strategy
Thomas S. Johnston, B.S., M.B.A

Vice President, Chief Financial Officer and Treasurer
Frederick W. Driscoll

Biographies

President and Chief Executive Officer
Rahul Singhvi, Sc.D., M.B.A.

Dr. Singhvi is a recognized vaccine specialist, manufacturing expert and business leader in the pharmaceutical industry. Since assuming his current position, Dr. Singhvi has restructured Novavax to focus on product innovation and development, in particular influenza vaccine development using the company’s novel virus-like particle and Novasome® paucilamellar vesicle technologies.

Before joining Novavax, Dr. Singhvi headed vaccine manufacturing operations at Merck & Co., where production increased by 25 percent at the two plants he oversaw.

Dr. Singhvi received his M.S. and Sc.D. degrees in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.    Dr. Singhvi also serves on the Board of Directors for the TechCouncil of Maryland . 

↑ Back to Top

Senior Vice President of Commercial Operations
Raymond J. Hage, Jr., M.B.A.

Mr. Hage is an experienced pharmaceutical marketer who has overseen the marketing of several major drugs over the past 15 years. Mr. Hage oversees business development and marketing strategy. Prior to joining Novavax, Mr. Hage held marketing positions at Eli Lilly & Co. and Cephalon, Inc.

Mr. Hage received a B.S. in Business and Economics from the University of Kentucky and an M.B.A. from Ohio State University.

↑ Back to Top

Senior Vice President of International and Government Alliances
John J. Trizzino, B.S., M.B.A.

Mr. Trizzino is responsible for international and government alliances at Novavax and joins Novavax with more than 28 years of broad industry experience.  Having worked closely with public and private partners including the U.S. Centers for Disease Control (CDC) and Prevention and the Department of Health and Human Services (HHS) he has an extensive background in vaccines. Mr. Trizzino served as Vice President, Vaccine Franchise at MedImmune, Inc., and was responsible for the FluMist® brand and public health sales teams, including the strategic planning and early execution of its international launch.  Before taking on vaccine franchise responsibilities Mr. Trizzino had responsibility for all trade activities for the $1 billion plus MAb RSV business.  Prior to joining MedImmune, Mr. Trizzino held positions at ID Biomedical (now GSK), including Senior Vice President, Business Development, and was in charge of the US launch of Fluviral® (GSK’s FluLaval®) and responsible for their bio defense vaccine business and government relations.  During his time at ID Biomedical, Mr. Trizzino also negotiated a $2.3 billion U.S. influenza vaccine distribution agreement for the company.

Mr. Trizzino obtained his M.B.A. from New York University, Leonard N. Stern School of Business, New York and his B.S. from Long Island University, NY.

↑ Back to Top

Dr. Smith is a leader in vaccine technology and holds numerous patents for the baculovirus-insect cell expression system, influenza vaccines and adjuvants. At Novavax, Dr. Smith has developed the first known commercial, scalable process for the manufacture of virus-like particle vaccines for influenza. He also has collaborated with the U.S. Centers for Disease Control and Prevention in testing a virus-like particle vaccine to protect animals against the H9N2 influenza. Prior to joining Novavax, Dr. Smith led a team at Protein Sciences Corp. that developed the first experimental vaccine for HIV approved by the U.S. Food and Drug Administration for testing in the United States. Dr. Smith also collaborated with the National Institute of Allergy and Infectious Diseases and the National Institute of Health to produce the first experimental vaccine tested in man against the H5N1 avian influenza.

Dr. Smith did graduate work at the Baylor College of Medicine and has a Ph.D. in Microbiology from Texas A&M University.

↑ Back to Top

Mr. Johnston is responsible for managing Novavax’s corporate strategic planning process, evaluating potential strategic opportunities and managing select initiatives, including the GE Healthcare collaboration, for development through to proof of concept.  Prior to joining Novavax, Mr. Johnston served as an executive level strategic consultant in a number of industries including biotech, financial services, and electronic security, with clients such as Novavax, RBC Bank and the U.S. Department of Homeland Security. Earlier in his career, Mr. Johnston held varying senior-level positions with a number of organizations such as Comcast, Microsoft, and Schlumberger.  In each role he was able to apply a unique combination of corporate strategy, marketing and finance skills with product level and often technical skills.  Tom holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

↑ Back to Top

Vice President, Chief Financial Officer and Treasurer
Frederick W. Driscoll